Article
Chemistry, Multidisciplinary
Guillem Pascual-Pasto, Helena Castillo-Ecija, Nora Unceta, Rosario Aschero, Claudia Resa-Pares, Alberto Gomez-Caballero, Monica Vila-Ubach, Oscar Munoz-Aznar, Mariona Sunol, Victor Burgueno, Soledad Gomez-Gonzalez, Alejandro Sosnik, Manuel Ibarra, Paula Schaiquevich, Enrique de Alava, Oscar M. Tirado, Jaume Mora, Angel M. Carcaboso
Summary: Secreted protein acidic and rich in cysteine (SPARC) promotes the accumulation of nanoparticle albumin-bound (nab)paclitaxel in pediatric sarcomas through its high affinity to albumin.
JOURNAL OF CONTROLLED RELEASE
(2022)
Review
Oncology
Youwen Chen, Rui Liu, Chenxi Li, Yurong Song, Guangzhi Liu, Qingcai Huang, Liuchunyang Yu, Dongjie Zhu, Cheng Lu, Aiping Lu, Linfu Li, Yuanyan Liu
Summary: Nab-paclitaxel improves water solubility and safety, inhibits microtubule depolymerization for anti-cancer effects, easily taken up by tumor and immune cells, and exhibits significant immunostimulatory activities to promote cancer-immunity cycle.
AMERICAN JOURNAL OF CANCER RESEARCH
(2021)
Article
Chemistry, Medicinal
Keiichiro Yoshioka, Mitsuhiro Abe, Yuki Shiko, Ken Koshikawa, Yohei Kawasaki, Shunichiro Iwasawa, Jiro Terada, Kenji Tsushima, Koichiro Tatsumi, Takuji Suzuki
Summary: This study retrospectively investigated 304 patients who received Nab-PTX treatment and found that 41 patients developed drug induced lung injury (DILI), with most cases being asymptomatic. Older age, pre-existing interstitial lung changes, and combined drugs with gemcitabine were identified as independent risk factors for Nab-PTX-induced lung injury.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Oncology
Kian-Huat Lim, Mateusz Opyrchal, Abhi Acharya, Nick Boice, Ningying Wu, Feng Gao, Jace Webster, Albert C. Lockhart, Saiama N. Waqar, Ramaswamy Govindan, Daniel Morgensztern, Joel Picus, Benjamin R. Tan, Maria Q. Baggstrom, Christopher A. Maher, Andrea Wang-Gillam
Summary: The study evaluated the efficacy and safety of the combination of AURKA inhibitor (alisertib) and paclitaxel in patients with refractory high-grade neuroendocrine tumors (NETs). The combination treatment demonstrated manageable side-effect profile and promising preliminary efficacy in high-grade NETs, warranting further testing.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Ari J. Rosenberg, Nishant Agrawal, Alexander T. Pearson, Zhen Gooi, Elizabeth Blair, Louis Portugal, John F. Cursio, Aditya Juloori, Jeffrey Chin, Kathryn Rouse, Victoria M. Villaflor, Tanguy Y. Seiwert, Evgeny Izumchenko, Mark W. Lingen, Daniel J. Haraf, Everett E. Vokes
Summary: This study evaluated the treatment for recurrent head and neck squamous cell carcinoma using induction therapy with carboplatin and nab-paclitaxel, followed by concomitant FHX and different doses of nab-paclitaxel. The study found that the recommended dose for nab-paclitaxel in combination with FHX was 100 mg/m(2).
BRITISH JOURNAL OF CANCER
(2022)
Article
Oncology
Chen Chang, Xiaofen Li, Ke Cheng, Zhaolun Cai, Junjie Xiong, Wanrui Lv, Ruizhen Li, Pei Zhang, Dan Cao
Summary: The study evaluated the toxicity and feasibility of gemcitabine/nab-paclitaxel/S-1 (GAS) chemotherapy on a 21-day cycle in patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC). The results showed that GAS chemotherapy had acceptable toxicity and significant clinical control in these patients.
Review
Biochemistry & Molecular Biology
Luigino Calzetta, Marina Aiello, Annalisa Frizzelli, Elena Pistocchini, Beatrice Ludovica Ritondo, Paola Rogliani, Alfredo Chetta
Summary: Inhaled corticosteroids (ICS) are the main treatment for asthma, but there is a need for innovative medications that selectively target components of inflammation. A review of recent randomized controlled trials identified 16 classes of novel therapeutic options, with lung function being the main assessed outcome. Promising disease-modifying agents, particularly biologics, are being studied, but further research is needed to confirm positive results from Phase I and II trials.
Article
Oncology
Priyanka Sharma, Vandana G. Abramson, Anne O'Dea, Lauren Nye, Ingrid Mayer, Harsh B. Pathak, Marc Hoffmann, Shane R. Stecklein, Manana Elia, Sharon Lewis, Jecinta Scott, Jilliann A. De Jong, Yen Y. Wang, Rachel Yoder, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Stephen K. Williamson, Milind A. Phadnis, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin
Summary: The combination of alpelisib and nab-paclitaxel showed good tolerability and promising efficacy in patients with HER2-negative metastatic breast cancer, especially in those with PIK3CA-mutated tumor/ctDNA. The impact of metabolic status on treatment response warrants further investigation.
CLINICAL CANCER RESEARCH
(2021)
Review
Biochemistry & Molecular Biology
Md Sazzad Hassan, Niranjan Awasthi, Saisantosh Ponna, Urs von Holzen
Summary: Taxanes, such as paclitaxel and docetaxel, are effective anticancer drugs but have high hydrophobicity and toxicity. Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) is a novel formulation that improves solubility, reduces toxicity, and allows higher doses and concentrations compared to solvent-based paclitaxel. It has been approved for metastatic breast cancer, NSCLC, and pancreatic adenocarcinoma. Clinical trials have also shown its potential efficacy in other gastrointestinal cancers. This review summarizes the advantages of nab-paclitaxel-based regimens in terms of improving clinical efficacy and safety profile in upper gastrointestinal cancer.
Article
Medicine, General & Internal
Wim Ceelen, Louis Sandra, Leen Van de Sande, Martin Graversen, Michael Bau Mortensen, An Vermeulen, Elke Gasthuys, Dries Reynders, Sarah Cosyns, Anne Hoorens, Wouter Willaert
Summary: In this Phase I study, the tolerability, safety, pharmacokinetics, and tumour response of nanoparticle albumin bound paclitaxel (NAB-PTX) during pressurized intraperitoneal aerosolized chemotherapy (PIPAC) were investigated. The results showed a favorable pharmacokinetic profile and promising anticancer activity of PIPAC with NAB-PTX in patients with unresectable peritoneal metastases.
Article
Oncology
Rocio Garcia-Carbonero, Miriam Bazan-Peregrino, Marta Gil-Martin, Rafael Alvarez, Teresa Macarulla, Maria C. Riesco-Martinez, Helena Verdaguer, Carmen Guillen-Ponce, Marti Farrera-Sal, Rafael Moreno, Ana Mato-Berciano, Maria Victoria Maliandi, Silvia Torres-Manjon, Marcel Costa, Natalia del Pozo, Jaime Martinez de Villarreal, Francisco X. Real, Noemi Vidal, Gabriel Capella, Ramon Alemany, Emma Blasi, Carmen Blasco, Manel Cascallo, Ramon Salazar
Summary: The study evaluates the safety and efficacy of VCN-01 adenovirus in patients with advanced cancer. The results show promising biological and clinical activity when administered in combination with nab-paclitaxel plus gemcitabine.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Hanwen Wang, Huilin Ma, Richard J. Sove, Leisha A. Emens, Aleksander S. Popel
Summary: This study introduces a modular quantitative systems pharmacology (QSP) platform for predicting immunotherapy efficacy and identifying predictive biomarkers. Virtual clinical trials were conducted using a virtual patient cohort generated by the model, with retrospective analysis and model validation based on clinical trial data.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Oncology
Carmen Criscitiello, Antonio Marra, Stefania Morganti, Paola Zagami, Sara Gandini, Angela Esposito, Giuseppe Curigliano
Summary: This study retrospectively analyzed the clinical characteristics and outcomes of patients with metastatic breast cancer treated with targeted therapy, immunotherapy, and combination therapy from 2014 to 2019 at a medical institution. The results showed that patients with triple negative breast cancer had poorer outcomes, and targeted therapy was associated with improved response rates and progression-free survival. Patients with fewer metastatic sites and baseline lactate dehydrogenase below the upper limit of normal had better overall survival.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Oncology
Tristan M. Sissung, William D. Figg
Summary: This article analyzes phase I clinical studies in oncology with a focus on pharmacogenetics. The findings suggest that current studies have small sample sizes, evaluate a limited number of genetic variants, and lack sufficient justification for pharmacogenetic hypotheses. Future studies should consider population heterogeneity and other confounding factors to optimize the design of phase I clinical trials and answer important scientific questions.
Review
Biochemistry & Molecular Biology
Seyed Samad Hosseini, Saeed Khalili, Behzad Baradaran, Negar Bidar, Mohammad-Ali Shahbazi, Jafar Mosafer, Mahmoud Hashemzaei, Ahad Mokhtarzadeh, Michael R. Hamblin
Summary: Bispecific antibodies (BsAbs) are now being applied to a wider range of diseases beyond cancer therapy, with various formats and construction technologies, aiming to stimulate immune responses against cancer cells. Over 20 commercial methods for BsAbs construction have been developed, with three BsAbs currently clinically approved and marketed, and over 85 clinical trials in progress.
INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
(2021)